MINNEAPOLIS, Oct. 10, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the second quarter of fiscal 2014 ended September 30, 2013 at the market close on Thursday, October 24, 2013. The Company will host a conference call to discuss these results on Thursday, October 24, 2013 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). Rob Kill, President and Chief Executive Officer, and Brett Reynolds, Chief Financial Officer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-8631. An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4643847#.
About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information: Uroplasty, Inc. Brett Reynolds, SVP and CFO 952.426.6152
EVC Group Leigh Salvo/ (Investors)/Janine McCargo (Business Media) 415.568.9348/646.688.0245
SOURCE Uroplasty, Inc.